{"id":2828,"date":"2026-08-24T23:40:48","date_gmt":"2026-08-24T23:40:48","guid":{"rendered":"https:\/\/officialcorepeptides.brandloom.net\/fr\/?post_type=product&p=2828"},"modified":"2026-08-24T23:40:49","modified_gmt":"2026-08-24T23:40:49","slug":"buy-follistatin-344-1mg-in-switzerland","status":"publish","type":"product","link":"https:\/\/officialcorepeptides.ch\/fr\/product\/buy-follistatin-344-1mg-in-switzerland\/","title":{"rendered":"Follistatin-344 (1MG)"},"content":{"rendered":"

What Is Follistatin-344 and Why Buy It for Research?<\/strong><\/h2>\n

Buy Follistatin-344 1mg in Switzerland for research into myostatin inhibition, TGF-\u03b2 superfamily signaling, and muscle growth regulation. Specifically, Follistatin-344 (also known as FS344, FST344, or activin-binding protein) is a full-length, naturally occurring glycoprotein composed of 344 amino acids. The \u00ab\u00a0344\u00a0\u00bb designation refers to the full-length precursor protein; after removal of a 29-amino acid signal peptide, the mature circulating form is known as FS-315 (315 amino acids).<\/p>\n

Nicholas Ling and colleagues first identified follistatin in 1987 from porcine ovarian follicular fluid based on its ability to suppress follicle-stimulating hormone (FSH) secretion \u2014 hence its name (follicle + statin). Subsequently, researchers recognized that follistatin exerts its FSH-suppressive effect by neutralizing activin, the primary stimulator of FSH synthesis. In scientific research, Follistatin-344 serves as a molecular tool for studying TGF-\u03b2 superfamily signaling, myostatin antagonism, and tissue plasticity. Furthermore, Core Peptides supplies Follistatin-344 as a lyophilized powder in a 1mg format exclusively for laboratory use. Therefore, researchers seeking to source this compound for their work will find it readily available when they buy Follistatin-344 1mg in Switzerland.<\/p>\n

Follistatin-344 Research Overview: Buy Follistatin-344 1mg in Switzerland for TGF-\u03b2 Signaling Studies<\/strong><\/h2>\n

Centrally, research into Follistatin-344 has focused on its function as a high-affinity binding protein for select members of the transforming growth factor-\u03b2 (TGF-\u03b2) superfamily. Follistatin-344 binds and neutralizes myostatin (GDF-8), activin A, activin B, and certain bone morphogenetic proteins (BMPs) through a wrapping mechanism that sterically blocks receptor engagement.<\/p>\n

Myostatin functions as a potent negative regulator of skeletal muscle growth by activating SMAD2\/3-dependent transcriptional programs that constrain myogenic differentiation. Follistatin-344 acts as an endogenous modulator by binding myostatin and limiting its receptor-mediated signaling cascade. The FST gene encodes Follistatin-344 and undergoes intracellular processing before secretion, with the precursor containing a signal peptide and core functional domains arranged to facilitate ligand interaction.<\/p>\n

The discovery that follistatin also binds and neutralizes myostatin \u2014 a powerful negative regulator of skeletal muscle mass \u2014 has generated extraordinary interest in follistatin as a potential therapeutic agent for muscle wasting diseases. Gene therapy approaches using FS-344 have entered clinical trials for Becker muscular dystrophy with promising early results. Accordingly, researchers who buy Follistatin-344 1mg in Switzerland from Core Peptides can support their investigations into TGF-\u03b2 signaling, myostatin inhibition, and muscle biology.<\/p>\n

How Does Follistatin-344 Work in Research?<\/strong><\/h2>\n

Mechanistically, Follistatin-344 functions as a ligand trap \u2014 also called a decoy receptor or neutralizing binding protein. Unlike a receptor antagonist that blocks a receptor, Follistatin-344 works by binding directly to TGF-\u03b2 superfamily ligands in the extracellular space, preventing them from interacting with their signaling receptors.<\/p>\n

Ligand Sequestration<\/strong><\/h3>\n

Follistatin-344 binds to its target ligands \u2014 myostatin, activins, and other TGF-\u03b2 family members \u2014 with high affinity. Structural studies show follistatin using its cystine-rich domains to wrap around the myostatin dimer like a clamp. This binding covers the receptor-binding surfaces on myostatin, prevents myostatin from docking onto activin receptor type IIB (ActRIIB), and forms a stable complex that is functionally inactive.<\/p>\n

The follistatin-ligand complex is essentially irreversible under physiological conditions, and the complex is unable to bind to type II activin receptors (ActRIIA\/ActRIIB) on cell surfaces. The bound complex is internalized via cell surface proteoglycans and degraded through lysosomal pathways. Consequently, the net effect is a reduction of available ligand for receptor activation.<\/p>\n

Blocking SMAD Signaling<\/strong><\/h3>\n

Under normal conditions, myostatin or activin binding to their receptors triggers a cascade known as SMAD signaling. This involves ligand binding to activin receptor type IIB and associated type I receptors, phosphorylation of SMAD2 and SMAD3 proteins, and formation of SMAD2\/3 complexes with SMAD4 that move into the nucleus to change gene expression \u2014 suppressing muscle growth and promoting protein breakdown.<\/p>\n

When Follistatin-344 binds myostatin and activins upstream, it reduces receptor activation and cuts down SMAD2\/3 phosphorylation. Without strong SMAD signaling, genes that limit muscle protein synthesis are downregulated, and genes that support growth, regeneration, and satellite cell activation are less suppressed.<\/p>\n

Structural Basis<\/strong><\/h3>\n

The distinction between Follistatin-344 and other isoforms, such as Follistatin-288, lies in differential C-terminal processing and heparan sulfate binding affinity. These isoform-specific features may influence tissue distribution, extracellular matrix interactions, and temporal availability.<\/p>\n

Why Is Follistatin-344 Studied in Switzerland?<\/strong><\/h2>\n

Primarily, researchers study Follistatin-344 because it represents a well-characterized glycoprotein that enables investigation of myostatin inhibition, TGF-\u03b2 signaling, and tissue plasticity. In fact, this compound offers a focused tool for studying the molecular mechanisms underlying muscle growth regulation, activin signaling, and growth factor modulation.<\/p>\n

Research has demonstrated Follistatin-344’s relevance across multiple domains. In preclinical research settings, exposure to Follistatin-344 results in altered activin- and myostatin-mediated signaling, with downstream effects on SMAD phosphorylation, transcriptional regulation, and cellular phenotype. Early 2000s research indicated that this peptide may double muscular tissue mass in experimental research models.<\/p>\n

Furthermore, gene-based exposure systems for Follistatin-344 may sustain elevated peptide levels over extended periods, potentially reducing myostatin and activin A concentrations and resulting in measurable improvements in lean mass (~10%) compared to controls. The peptide has been hypothesized to support satellite cell activation and muscle cell repair and regeneration.<\/p>\n

Beyond muscle research, Follistatin-344’s engagement with activin and myostatin may extend to metabolic regulation. Research suggests that overexpression of Follistatin-344 may promote \u03b2-cell proliferation in pancreatic islets, potentially increasing insulin secretion and attenuating diabetic phenotypes. Additionally, the peptide may support osteogenesis, leading to increased bone formation and density, and has been theorized to attenuate fibrotic deposition by limiting activin-mediated pathways. Ultimately, researchers who buy Follistatin-344 1mg in Switzerland gain access to a comprehensive research tool for investigating TGF-\u03b2 superfamily signaling, myostatin inhibition, and tissue plasticity.<\/p>\n

Follistatin-344 Research Areas in Laboratory Studies<\/strong><\/h2>\n\n\n\n\n\n\n\n\n\n\n\n
Research Area<\/th>\nFocus<\/th>\nKey Applications<\/th>\n<\/tr>\n<\/thead>\n
Myostatin Inhibition<\/td>\nMuscle growth regulation, SMAD2\/3 signaling blockade<\/td>\nFS344<\/td>\n<\/tr>\n
TGF-\u03b2 Superfamily Signaling<\/td>\nActivin sequestration, BMP modulation, receptor-ligand interactions<\/td>\nFS344<\/td>\n<\/tr>\n
Skeletal Muscle Hypertrophy<\/td>\nMuscle fiber size, satellite cell activity, protein synthesis<\/td>\nFS344<\/td>\n<\/tr>\n
Neuromuscular Research<\/td>\nMotor neuron maintenance, neuromuscular preservation<\/td>\nFS344<\/td>\n<\/tr>\n
Metabolic Regulation<\/td>\n\u03b2-cell proliferation, insulin secretion, glucose homeostasis<\/td>\nFS344<\/td>\n<\/tr>\n
Fibrosis Research<\/td>\nActivin-mediated fibrotic pathways, hepatic fibrosis attenuation<\/td>\nFS344<\/td>\n<\/tr>\n
Osteogenesis<\/td>\nBone formation, bone density, activin\/myostatin effects<\/td>\nFS344<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Follistatin-344 Compared With Related Research Compounds<\/strong><\/h2>\n\n\n\n\n\n\n\n\n
Compound<\/th>\nResearch Focus<\/th>\nMechanism \/ Target<\/th>\nKey Difference<\/th>\n<\/tr>\n<\/thead>\n
Follistatin-344 (FS344)<\/td>\nMyostatin inhibition, TGF-\u03b2 signaling, muscle growth<\/td>\nLigand trap (myostatin, activins, BMPs)<\/td>\n344-aa precursor; full-length follistatin isoform<\/td>\n<\/tr>\n
Follistatin-288 (FS288)<\/td>\nActivin inhibition, TGF-\u03b2 signaling<\/td>\nLigand trap (activin, myostatin)<\/td>\n288-aa isoform; higher activin affinity; cell-surface binding<\/td>\n<\/tr>\n
ACE-031<\/td>\nMyostatin inhibition, muscle growth<\/td>\nActRIIB-Fc fusion protein (decoy receptor)<\/td>\nFusion protein; different mechanism<\/td>\n<\/tr>\n
Myostatin Propeptide<\/td>\nMyostatin inhibition<\/td>\nLatent myostatin binding<\/td>\nDifferent binding mechanism<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Comparatively, Follistatin-344 differs from other myostatin inhibitors in its mechanism and isoform-specific properties. On the one hand, Follistatin-344 is a full-length glycoprotein that functions as a ligand trap, binding directly to myostatin and activins. On the other hand, ACE-031 is a recombinant fusion protein that acts as a decoy receptor by joining a portion of the human ActRIIB receptor to a portion of a human antibody. In contrast, Follistatin-288 has higher activin affinity and cell-surface binding due to its C-terminal processing. FS344 has a 10-fold lower affinity to activin compared to FS288, making it the preferred isoform for muscle-specific research applications.<\/p>\n

Research Applications for Follistatin-344 in Switzerland<\/strong><\/h2>\n

Scientists have investigated Follistatin-344 across several research domains:<\/p>\n